EUROAPI and BianoGMP, a contract development and manufacturing organization (CDMO) with expertise in oligonucleotides, signed a share purchase and transfer agreement under which EUROAPI will acquire BianoGMP in a €10 million transaction. The acquisition aims to increase Biano’s capacity to address larger scale and more complex projects.

Biano, based in Germany, is an oligonucleotide CDMO player focused on small-scale, early-stage, complex and customized projects, with a diversified client base in Europe and Asia. The acquisition will strengthen EUROAPI’s CDMO market position in oligonucleotides with capacity to grow.

The planned expansion of EUROAPI’s Frankfurt oligonucleotide capacity in 2025 will be complementary to Biano’s early-phase expertise and enable larger-scale projects. In addition to opening opportunities for cross-referral commercial synergies and scientific cooperation, the transaction will further EUROAPI’s value proposition to accompany a wider client base across the whole oligonucleotide development continuum, from research to commercialization.

Biano will retain its corporate brand and become a EUROAPI company.

“The acquisition of Biano builds on EUROAPI’s strategy to accelerate its CDMO roadmap through vertical integration and strengthen its highly differentiated platforms, notably oligonucleotide activity,” said Karl Rotthier, CEO of EUROAPI. “By coupling Biano’s expertise and capacity in early-stage projects with EUROAPI’s larger scale capabilities, we aim to support our clients along the drug development pathway as a one-stop shop. This bolt-on transaction is a key milestone in our journey to become a leading, fast-growing CDMO company.”